112 related articles for article (PubMed ID: 6927305)
1. View from the Nation's Capitol.
Freishtat HW
J Clin Psychopharmacol; 1982 Jun; 2(3):219-20. PubMed ID: 6927305
[No Abstract] [Full Text] [Related]
2. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1983 Feb; 3(1):47-8. PubMed ID: 6680403
[No Abstract] [Full Text] [Related]
3. View from the Nation's Capitol.
Freishtat HW
J Clin Psychopharmacol; 1982 Apr; 2(2):146-8. PubMed ID: 6926924
[No Abstract] [Full Text] [Related]
4. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1984 Jun; 4(3):161-2. PubMed ID: 6096408
[No Abstract] [Full Text] [Related]
5. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1983 Oct; 3(5):319-21. PubMed ID: 6680407
[No Abstract] [Full Text] [Related]
6. View from the Nation's Capital.
Freishtat HW
J Clin Psychopharmacol; 1985 Apr; 5(2):117-9. PubMed ID: 3988970
[No Abstract] [Full Text] [Related]
7. View from the Nation's Capitol.
Romansky MA
J Clin Psychopharmacol; 1982 Feb; 2(1):74-5. PubMed ID: 6926923
[No Abstract] [Full Text] [Related]
8. [Orphan drugs--competing for a better name in Sweden].
Karlsson Y
Lakartidningen; 1990 Feb; 87(9):658. PubMed ID: 2308437
[No Abstract] [Full Text] [Related]
9. The fuel to run the orphan drug engine: a medical school-based Orphan Disease Center Program.
Brewer GJ
Prog Clin Biol Res; 1985; 197():123-38. PubMed ID: 4070287
[No Abstract] [Full Text] [Related]
10. Should the patent system for new medicines be abolished?
DiMasi JA; Grabowski HG
Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
[No Abstract] [Full Text] [Related]
11. Should off-label drug use be off-the-table?
Rivkees SA
J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
[No Abstract] [Full Text] [Related]
12. Orphan Drug Act.
Science; 1990 Jul; 249(4967):346-7. PubMed ID: 2377889
[No Abstract] [Full Text] [Related]
13. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
Karst KR
Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
[No Abstract] [Full Text] [Related]
14. Perspectives. Orphan Drug Act stumps lawmakers.
Firshein J
Faulkner Grays Med Health; 1990 Jun; 44(25):suppl 4 p.. PubMed ID: 10105023
[No Abstract] [Full Text] [Related]
15. View from the Nation's Capital.
Appler WD
J Clin Psychopharmacol; 1987 Jun; 7(3):185-6. PubMed ID: 3597806
[No Abstract] [Full Text] [Related]
16. Orphan Drug Act on congressional agenda.
von Oehsen WH
Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123
[TBL] [Abstract][Full Text] [Related]
17. Orphan drug development in the United States.
Groft SC
CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
[TBL] [Abstract][Full Text] [Related]
18. Orphan drug development for the treatment of rare chronic diseases.
Moore ES
Tex Hosp; 1988 Jul; 44(2):20-1. PubMed ID: 10288218
[No Abstract] [Full Text] [Related]
19. View from the Nation's Capital.
Appler WD
J Clin Psychopharmacol; 1986 Feb; 6(1):42-4. PubMed ID: 3950066
[No Abstract] [Full Text] [Related]
20. EU adopts legislation to promote drug development for rare diseases.
Whyte B
Bull World Health Organ; 2000; 78(5):711. PubMed ID: 10859868
[No Abstract] [Full Text] [Related]
[Next] [New Search]
